Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.

NCT05340413 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

HER2-negative Breast Cancer
Metastatic Breast Cancer
Triple Negative Breast Cancer

Interventions

DRUG: Olaparib

Sponsor

SOLTI Breast Cancer Research Group